Patent DE128197C successfully refreshed from Google Patents.
US4032641A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nicotinoyl carnitine derivatives
Assignee: Tanabe Pharma Corp
•
Filing: 1976-06-09
•
Granted: 1977-06-28
•
Expires: 1996-06-09
Abstract
Abstract A nicotinoyl carnitine compound of the formula: <IMAGE> [I] wherein R is lower alkoxy, benzyloxy or amino and X is an anionic residue of a pharmaceutically acceptable acid, is prepared by reacting a carnitine derivative of the formula: <IMAGE> [II] wherein R is the same as defined above, with nicotinic acid or a functional derivative thereof. The derivative [I] and the pharmaceutically acceptable acid addition salts of said compound are useful as hypolipidemic agents.
Inventors
- 👤 Ichiro Chibata
- 👤 Munetsugu Miyoshi
- 👤 Kohki Takashima
- 👤 Shoji Moriya
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 11:40
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/78; C07D213/79; C07D213/80
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
35 words
A compound of the formula: ##STR6## wherein R is lower alkoxy, benzyloxy or amino and X is an anionic residue of a pharmaceutically acceptable acid, or a pharmaceutically acceptable acid addition salt of said compound.
Claim 2
Dependent Claim
35 words
A compound of the formula: ##STR6## wherein R is lower alkoxy, benzyloxy or amino and X is an anionic residue of a pharmaceutically acceptable acid, or a pharmaceutically acceptable acid addition salt of said compound.
Claim 3
Dependent Claim
12 words
The compound claimed in claim 1, in which R is lower alkoxy.
Claim 4
Dependent Claim
11 words
The compound claimed in claim 1, in which R is benzyloxy.
Claim 5
Dependent Claim
11 words
The compound claimed in claim 1, in which R is amino.
Claim 6
Dependent Claim
43 words
The compound claimed in claim 1, in which R is methyl, ethyl, butyl or benzyloxy, and X is an ion selected from the group consisting of halide, nitrate, sulfate, phosphate, chlorate, bromate, lower alkane-monocarboxylate, lower alkene-dicarboxylate, lower alkane-dicarboxylate, lower alkyl-sulfonate, benzenesulfonate and toluenesulfonate.
Claim 7
Dependent Claim
7 words
Nicotinoyl carnitine ethyl ester nitrate.HNO 3 .
Claim 8
Dependent Claim
7 words
Nicotinoyl carnitine ethyl ester nitrate.HNO 3 .
Claim 9
Dependent Claim
5 words
Nicotinoyl carnitine ethyl ester phosphate.
Claim 10
Dependent Claim
5 words
Nicotinoyl carnitine ethyl ester phosphate.
Claim 11
Dependent Claim
5 words
Nicotinoyl carnitine ethyl ester chloride.
Claim 12
Dependent Claim
5 words
Nicotinoyl carnitine ethyl ester chloride.
Claim 13
Dependent Claim
5 words
Nicotinoyl carnitine ethyl ester chloride.HCl.
Claim 14
Dependent Claim
5 words
Nicotinoyl carnitine ethyl ester chloride.HCl.
Claim 15
Dependent Claim
15 words
The compound claimed in claim 1, in which R is methoxy, ethoxy, butoxy or benzyloxy.
Claim 16
Dependent Claim
56 words
A therapeutic composition, useful as a hypolipidemic agent, which comprises a therapeutically effective amount of a compound of the formula: ##STR7## wherein R is lower alkoxy, benzyloxy or amino and X is an anionic residue of a pharmaceutically acceptable acid, or a pharmaceutically acceptable acid addition salt of said compound, and a pharmaceutically acceptable carrier therefor.
Claim 17
Dependent Claim
56 words
A therapeutic composition, useful as a hypolipidemic agent, which comprises a therapeutically effective amount of a compound of the formula: ##STR7## wherein R is lower alkoxy, benzyloxy or amino and X is an anionic residue of a pharmaceutically acceptable acid, or a pharmaceutically acceptable acid addition salt of said compound, and a pharmaceutically acceptable carrier therefor.
Claim 18
Dependent Claim
25 words
The composition of claim 10 wherein said therapeutic amount is that which is necessary to produce a hypolipidemic effect by administration to a warm-blooded animal.
Claim 19
Dependent Claim
21 words
The composition of claim 10 wherein said therapeutic amount for an adult patient is 200 mg to 10 g per day.
References Cited (Backward Citations)
US3337569A
Cited
FR2162334A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-27 | 1980-12-27 | 1981-06-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-27 | 1984-12-27 | 1985-06-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-27 | 1988-12-27 | 1989-06-28 | $7700.00 | Window Closed / Lapsed |